Traws Pharma, Inc. TRAW 深 滬
已收盤 05-08 16:00:00 美东时间
2.18
+0.480
+28.24%
華盛通- 最 高2.3999
- 今 開2.05
- 成交量 8946.13万股
- 最 低 1.79
- 昨 收 1.70
- 總市值 3302.85万
- 52周最高 3.265
- 市盈率 靜 1.99
- 換手率 590.48%
- 52周最低 0.995
- 委 比 -12.60%
- 總股本 1515.07万
- 歷史最高 1751062.50
- 量 比 713.47
- 振 幅 35.88%
- 歷史最低 0.97
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Traws Pharma Announces Plans To Advance Potential Clinical Candidates For The Treatment Of Hantavirus Infection
Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral
05-08 19:32
Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.69) by 2.9 percent. This is a 85.8 percent increase over losses of $(5.00) per share from the
04-16 04:25
Traws Pharma Prices $10M PIPE At $1.673/Share For 5.98M Shares, Issues Warrants For Up To 29.9M Shares With $50M Additional Upside Potential
Entry into a Material Definitive Agreement PIPE Securities Purchase Agreement On April 15, 2026, Traws Pharma, Inc. (the "Company") announced the pricing of an offering (the "Private Placement") of an aggregate
04-15 20:17
Traws Pharma Completed Clinical Analysis Of Its 90-patient, Open-label Phase 2 Study Of Ratutrelvir Versus Paxlovid For Mild-to-moderate Covid-19
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were
02-19 20:36
Traws Pharma Completes Enrollment In Ongoing 90-Patient, Open-Label Phase 2 Study Of Ratutrelvir, Investigational Oral, Ritonavir-Free Mpro/3CL Protease Inhibitor, Versus PAXLOVID, In COVID-19 Patients
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated
01-26 21:32
Traws Pharma shares are trading higher after the company announced the filing of a U.S. IND application with FDA for tivoxavir marboxil to treat influenza.
Traws Pharma shares are trading higher after the company announced the filing o...
01-14 03:01
Traws Pharma's Interim Data For Ratutrelvir Demonstrated A Differentiated Clinical Profile In Pre-specified Interim Analysis Of An Ongoing Open-label Phase 2 Study For Mild-to-moderate Covid-19, Final Data Analysis Expected In January 2026
The study was designed as an active-controlled comparator trial versus PAXLOVID™ (nirmatrelvir/ritonavir) and evaluated patient-reported symptom outcomes, safety, and real-world usability. A separate treatment arm
2025-12-17 19:02
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
HC Wainwright & Co. Initiates Coverage On Traws Pharma with Buy Rating, Announces Price Target of $8
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Traws Pharma (NASDAQ:TRAW) with a Buy rating and announces Price Target of $8.
2025-12-03 20:00
Traws Pharma’s TRX-100 Study: A Potential Game-Changer in Pharmacokinetics
Traws Pharma, Inc. (($TRAW)) announced an update on their ongoing clinical stud...
2025-10-28 00:59
